Results 11 to 20 of about 2,693 (166)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan

Microbiology Spectrum, 2022
Relebactam is a novel β-lactamase inhibitor of Ambler class A and C β-lactamases that has been developed in combination with imipenem/cilastatin for the treatment of carbapenem-resistant bacterial infections.
Dai Kurihara, Satoru Matsumoto, Naoko Kishi, Yoshikazu Ishii, Masahiko Mori   +4 more
doaj   +3 more sources

Role of Relebactam in the Antibiotic Resistance Acquisition in Pseudomonas aeruginosa: In Vitro Study

Antibiotics, 2023
Background: Pseudomonas aeruginosa shows resistance to several antibiotics and often develops such resistance during patient treatment. Objective: Develop an in vitro model, using clinical isolates of P. aeruginosa, to compare the ability of the imipenem
Maria Paz Ventero, Jose M. Haro-Moreno, Carmen Molina-Pardines, Antonia Sánchez-Bautista, Celia García-Rivera, Vicente Boix, Esperanza Merino, Mario López-Pérez, Juan Carlos Rodríguez   +8 more
doaj   +5 more sources

In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex [PDF]

The Cell Surface, 2021
Infections resulting from Mycobacterium abscessus are increasing in prevalence worldwide, with the greatest risk posed to patients with underlying respiratory conditions.
James Harrison, John A. Weaver, Maya Desai, Jonathan A.G. Cox   +3 more
doaj   +3 more sources

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa [PDF]

BMC Microbiology, 2019
Background The prevalence of antibiotic resistance is increasing, and multidrug-resistant Pseudomonas aeruginosa has been identified as a serious threat to human health. The production of β-lactamase is a key mechanism contributing to imipenem resistance
Katherine Young, Ronald E. Painter, Susan L. Raghoobar, Nichelle N. Hairston, Fred Racine, Douglas Wisniewski, Carl J. Balibar, Artjohn Villafania, Rumin Zhang, Daniel F. Sahm, Timothy Blizzard, Nicholas Murgolo, Milton L. Hammond, Mary R. Motyl   +13 more
doaj   +3 more sources

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2019
Relebactam is a small‐molecule β‐lactamase inhibitor developed as a fixed‐dose combination with imipenem/cilastatin. The pharmacokinetics of relebactam and imipenem across 10 clinical studies were analyzed using data from adult healthy volunteers and ...
Pratik Bhagunde, Parul Patel, Mallika Lala, Kenny Watson, William Copalu, Ming Xu, Pooja Kulkarni, Katherine Young, Matthew L. Rizk   +8 more
doaj   +3 more sources

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections [PDF]

Drugs, 2021
Imipenem/cilastatin/relebactam (Recarbrio™) is an intravenously administered combination of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel β-lactamase inhibitor relebactam. Relebactam is a potent inhibitor of class A and class C β-lactamases, conferring imipenem activity against many imipenem-nonsusceptible ...
Mansour, Hanine, Oweini, Ahmad E. L, Chahine, Elias B., Karaoui, Lamis R.   +3 more
openaire   +6 more sources

Klebsiella pneumoniae Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio

Biomedicines, 2022
The inoculum effect (IE) is a well-known phenomenon with beta-lactams. At the same time, the IE has not been extensively studied with carbapenem/carbapenemase inhibitor combinations.
Maria V. Golikova, Kamilla N. Alieva, Alla V. Filimonova, Vladimir A. Ageevets, Ofeliia S. Sulian, Alisa A. Avdeeva, Sergey V. Sidorenko, Stephen H. Zinner   +7 more
doaj   +1 more source

AmpC β-lactamase induction by avibactam and relebactam [PDF]

Journal of Antimicrobial Chemotherapy, 2017
Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.Levels of ampC mRNA were measured by RT-PCR during 4 h of exposure of Enterobacter cloacae, Citrobacter freundii and Pseudomonas aeruginosa (n = 5 ...
Livermore, David M, Jamrozy, Dorota, Mushtaq, Shazad, Nichols, Wright W, Young, Katherine, Woodford, Neil   +5 more
openaire   +4 more sources

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria

Antibiotics, 2023
Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to aztreonam.
Cécile Emeraud, Sandrine Bernabeu, Laurent Dortet   +2 more
doaj   +1 more source

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam

Revista Española de Quimioterapia, 2022
Imipenem combined with beta-lactamase inhibitor relebactam (IMI/REL) has an extensive bactericidal activity against Gram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase 3 clinical trial (RESTORE-IMI-2), double-blind, randomized, evaluated IMI/REL vs.
Girón, R M, Ibáñez, A, Gómez-Punter, R M, Alarcón, T   +3 more
openaire   +4 more sources